
Overview
Dr. Michael L. Cheng is a medical oncologist who cares for patients with lung cancer and other tumors affecting the chest, with a particular focus on non-small cell lung cancer. He strives to provide individualized, compassionate care through precision oncology (using the genetic profile of the patient's cancer to custom-tailor treatment). Cheng leads research centered on developing innovative, next-generation treatments for lung cancer, including therapeutic clinical trials with new targeted therapies and immunotherapies. He is inspired by how research discoveries can lead to tangible benefits for patients. Cheng earned his medical degree from the David Geffen School of Medicine at UCLA. He completed a residency in internal medicine at UCSF and a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Before joining the UCSF faculty, he served as an assistant professor at the Dana-Farber Cancer Institute and Harvard Medical School. Cheng is a member of the American Society of Clinical Oncology (ASCO) and International Association for the Study of Lung Cancer. He has received the Career Development Award from Conquer Cancer, the ASCO Foundation, as well as research funding from the National Institutes of Health and National Cancer Institute.
Dr. Cheng is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Large-Cell Lung Carcinoma, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma.
Dr. Cheng is board certified in American Board Of Internal Med/Medical Oncology, Medical Oncology and American Board Of Internal Medicine, Internal Medicine. Dr. Cheng is currently accepting new patients.
Graduate Institution
Residency
Specialties
Licenses
Board Certifications
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- MEDICARE SNP
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
1825 Fourth St., Sixth Floor, San Francisco, CA 94158
Breast Care Center
Hope Rugo is an Oncologist practicing medicine in San Francisco, California. Dr. Rugo is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Bone Marrow Aspiration, and Hormone Replacement Therapy (HRT).
Endocrine Surgery And Oncology Clinic
Dr. Julie Ann Sosa is an endocrine surgeon who specializes in thyroid cancer. She also has expertise in treating adults and children for a variety of benign and malignant endocrine conditions of the thyroid, parathyroid and adrenal glands. She chairs the UCSF Department of Surgery. Sosa's research focuses on developing treatments for advanced thyroid cancer and understanding environmental factors that can raise a person's risk for the disease. She also has published extensively on predictors of optimal patient outcomes following a variety of cancer-based procedures. Sosa earned her medical degree at Johns Hopkins University School of Medicine, where she also completed the Halsted residency in general surgery and served as chief resident. She completed a fellowship in clinical research with the Robert Wood Johnson Foundation at Johns Hopkins, where she was also assistant chief of service and an instructor. She has a master's degree in human sciences from the University of Oxford. Prior to joining UCSF, she was chief of endocrine surgery at Duke University, and held leadership positions at the Duke Cancer Institute and Duke Clinical Research Institute. Sosa is a fellow of the American College of Surgeons. She is the elected editor-in-chief of the World Journal of Surgery, and had previous positions as deputy editor of JAMA Surgery and associate editor of the Journal of Surgical Research. She serves on the editorial boards of seven medical journals, including the Annals of Surgery, Surgery, Annals of Surgical Oncology, Endocrine and International Journal of Endocrine Oncology. She serves on the boards of the Society of Surgical Oncology, International Thyroid Oncology Group, Association for Academic Surgery Foundation and American Thyroid Association, where she is also treasurer. She is the Leon Goldman, MD Distinguished Professor of Surgery at UCSF. Sosa was born in Montréal and raised in upstate New York. Dr. Sosa is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Thyroid Cancer, Papillary Thyroid Cancer, Parathyroid Hyperplasia, Thyroidectomy, and Parathyroidectomy. Dr. Sosa is board certified in American Board Of Surgery, General Surgery. Dr. Sosa is currently accepting new patients.
Prostate Cancer Center
Dr. Sima Porten is a specialist in cancers of the genital and urinary organs. She is a member of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center. Her clinical interests include the diagnosis and treatment of genitourinary cancer, particularly bladder cancer, upper tract urothelial cancer, kidney cancer and high-risk prostate cancer. Porten's research focuses mainly on the diagnosis and management of urothelial carcinoma, a cancer involving parts of the kidney, bladder and ureter (the tube connecting each kidney to the bladder). In studying the biologic or genetic basis of urothelial carcinoma, she hopes to develop new tests and treatments to bring personalized medicine to patients with bladder cancer. Porten received her undergraduate, medical and master of public health degrees from Northwestern University. During medical school, she was inducted into the Alpha Omega Alpha Honor Medical Society and also completed a fellowship through the Howard Hughes Medical Institute–National Institutes of Health Research Scholars Program. She then completed her urology residency training at UCSF, where she received the Julius R. Krevans Award for Clinical Excellence. During her training in urologic oncology at the University of Texas MD Anderson Cancer Center, she was awarded a John Quale Travel Fellowship for her research in bladder cancer. Porten is an active member of the American Urological Association, American Society of Clinical Oncology, Society of Women in Urology and Society of Urologic Oncology. Dr. Porten is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Porten is board certified in American Board Of Urology, Urology. Dr. Porten is currently accepting new patients.
Frequently Asked Questions about Dr. Michael L. Cheng
How do I make an appointment with Dr. Michael L. Cheng?
You can book an appointment with Dr. Michael L. Cheng by calling their office at 415-885-3882. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Michael L. Cheng a top-rated expert for Small Cell Lung Cancer (SCLC)?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael L. Cheng is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Michael L. Cheng specialize in?
While Dr. Michael L. Cheng is a Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Large-Cell Lung Carcinoma, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.
Does Dr. Michael L. Cheng accept my insurance?
Dr. Michael L. Cheng accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 415-885-3882 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- ALK-Positive Non-Small Cell Lung CancerDr. Cheng isDistinguished. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- EGFR Positive Lung CancerDr. Cheng isDistinguished. Learn about EGFR Positive Lung Cancer.
- Large-Cell Lung CarcinomaDr. Cheng isDistinguished. Learn about Large-Cell Lung Carcinoma.
- Lung AdenocarcinomaDr. Cheng isDistinguished. Learn about Lung Adenocarcinoma.
- Lung CancerDr. Cheng isDistinguished. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)Dr. Cheng isDistinguished. Learn about Non-Small Cell Lung Cancer (NSCLC).
- Experienced
- MesotheliomaDr. Cheng isExperienced. Learn about Mesothelioma.
- Metastatic Brain TumorDr. Cheng isExperienced. Learn about Metastatic Brain Tumor.
- Metastatic Pleural TumorDr. Cheng isExperienced. Learn about Metastatic Pleural Tumor.
- Posterior Fossa TumorDr. Cheng isExperienced. Learn about Posterior Fossa Tumor.
- Primitive Neuroectodermal Tumor (PNET)
- Thymic Epithelial TumorDr. Cheng isExperienced. Learn about Thymic Epithelial Tumor.


